Newborn Screening for Sickle Cell Disease in Catalonia between 2015 and 2022-Epidemiology and Impact on Clinical Events.


Por: González de Aledo-Castillo JM, Argudo-Ramírez A, Beneitez-Pastor D, Collado-Gimbert A, Almazán Castro F, Roig-Bosch S, Andrés-Masó A, Ruiz-Llobet A, Pedrals-Portabella G, Medina-Santamaria D, Nadal-Rey G, Espigares-Salvia M, Coll-Sibina MT, Algar-Serrano M, Torrent-Español M, Leoz-Allegretti P, Rodríguez-Pebé A, García-Bernal M, Solà-Segura E, García-Gallego A, Prats-Viedma B, López-Galera RM, Paredes-Fuentes AJ, Pajares García S, Delgado-López G, Blanco-Álvarez A, Tazón-Vega B, Díaz de Heredia C, Mañú-Pereira MDM, Marín-Soria JL, García-Villoria J, Velasco-Puyó P and On Behalf Of The Sickle Cell Disease Newborn Screening Group Of Catalonia

Publicada: 3 oct 2024 Ahead of Print: 3 oct 2024
Resumen:
In 2015, Catalonia introduced sickle cell disease (SCD) screening in its newborn screening (NBS) program along with standard-of-care treatments like penicillin, hydroxyurea, and anti-pneumococcal vaccination. Few studies have assessed the clinical impact of introducing NBS programs on SCD patients. We analyzed the incidence of SCD and related hemoglobinopathies in Catalonia and the change in clinical events occurring after introducing NBS. Screening 506,996 newborns from 2015 to 2022, we conducted a retrospective multicenter study including 100 screened (SG) and 95 unscreened (UG) SCD patients and analyzed SCD-related clinical events over the first six years of life. We diagnosed 160 cases of SCD, with an incidence of 1 in 3169 newborns. The SG had a significantly lower median age at diagnosis (0.1 y vs. 1.68 y, p < 0.0001), and initiated penicillin prophylaxis (0.12 y vs. 1.86 y, p < 0.0001) and hydroxyurea treatment earlier (1.42 y vs. 4.5 y, p < 0.0001). The SG experienced fewer median SCD-related clinical events (vaso-occlusive crisis, acute chest syndrome, infections of probable bacterial origin, acute anemia requiring transfusion, acute splenic sequestration, and pathological transcranial Doppler echography) per year of follow-up (0.19 vs. 0.77, p < 0.0001), a reduced number of annual emergency department visits (0.37 vs. 0.76, p < 0.0001), and fewer hospitalizations (0.33 vs. 0.72, p < 0.0001). SCD screening in Catalonia's NBS program has effectively reduced morbidity and improved affected children's quality of life.

Filiaciones:
González de Aledo-Castillo JM:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

Argudo-Ramírez A:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

Beneitez-Pastor D:
 Hematology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain

Collado-Gimbert A:
 Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain

Almazán Castro F:
 Pediatric Hematology Unit, Hospital Germans Trias i Pujol, 08916 Badalona, Spain

Roig-Bosch S:
 Pediatric Department, Hospital Santa Caterina, Institut d'Assistència Sanitària, 17190 Salt, Spain

Andrés-Masó A:
 Pediatric Department, Hospital Santa Caterina, Institut d'Assistència Sanitària, 17190 Salt, Spain

Ruiz-Llobet A:
 Pediatric Oncology and Hematology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain

Pedrals-Portabella G:
 Pediatric Oncology and Hematology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain

Medina-Santamaria D:
 Pediatric Hematology Unit, Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain

Nadal-Rey G:
 Pediatric Department, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain

Espigares-Salvia M:
 Pediatric Department, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain

Coll-Sibina MT:
 Pediatric Hematology Unit, Hospital General de Granollers, 08402 Granollers, Spain

Algar-Serrano M:
 Pediatric Department, Hospital de Figueres, 17600 Figueres, Spain

Torrent-Español M:
 Pediatric Oncology and Hematology Department, Hospital de Sant Pau, 08041 Barcelona, Spain

Leoz-Allegretti P:
 Hematology Department, Hospital de Sant Pau, 08041 Barcelona, Spain

Rodríguez-Pebé A:
 Pediatric Hematology Department, Consorci Sanitari del Maresme, 08304 Mataró, Spain

García-Bernal M:
 Pediatric Hematology Department, Consorci Sanitari de Terrassa, 08227 Terrassa, Spain

 Pediatric Hematology Department, Hospital Universitari Mútua de Terrassa, 08221 Terrassa, Spain

Solà-Segura E:
 Institut Català de la Salut (ICS) Catalunya Central, 08500 Vic, Spain

García-Gallego A:
 Institut Català de la Salut (ICS) Catalunya Central, 08500 Vic, Spain

Prats-Viedma B:
 Maternal and Child Health Service, Public Health Agency of Catalonia (APSCAT), Department of Health, Generalitat de Catalunya, 08005 Barcelona, Spain

López-Galera RM:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

 Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, 28029 Madrid, Spain

 Biomedical Research Institute, August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain

:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

Pajares García S:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

 Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, 28029 Madrid, Spain

Delgado-López G:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

Blanco-Álvarez A:
 Hematology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain

Tazón-Vega B:
 Hematology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain

Díaz de Heredia C:
 Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain

Mañú-Pereira MDM:
 Rare Anemia Disorders Research Laboratory, Cancer and Blood Disorders Research Group, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain

Marín-Soria JL:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

García-Villoria J:
 Section of Inborn Errors of Metabolism, Department of Biochemistry and Molecular Genetics, Hospital Clínic de Barcelona, 08028 Barcelona, Spain

 Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, 28029 Madrid, Spain

 Biomedical Research Institute, August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain

Velasco-Puyó P:
 Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain
ISSN: 2409515X





International Journal of Neonatal Screening
Editorial
MDPI, MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 10 Número: 4
Páginas:
WOS Id: 001385684900001
ID de PubMed: 39449357
imagen gold

MÉTRICAS